No Data
No Data
Press Release: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced t
BioCryst Pharmaceuticals Says Drug Shows Evidence of Reducing Attacks Among Hereditary Angioedema Patients
BioCryst Pharmaceuticals (BCRX) said Sunday an analysis showed that six patients with hereditary angioedema experienced a reduction in monthly attacks while taking oral, once-daily Orladeyo. BioCryst
BioCryst Announced Data Showing Reductions In Attack Rates In HAE Patients With Normal C1-Inhibitor After Beginning ORLADEYO Treatment
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and functio
BioCryst Pharmaceuticals(BCRX.US) Director Buys US$49,995.96 in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Director LEVIN ALAN G purchased 7,861 shares of common stock on May 30, 2024 at an average price of $6.36 for a total value of $49,995.96.Source: Announcement What
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): When Will It Breakeven?
We feel now is a pretty good time to analyse BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) business as it appears the company may be on the cusp of a considerable accomplishment. BioCryst Pharmaceu
BioCryst Pharmaceuticals(BCRX.US) Director Buys US$16,000 in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.Source: Announcement What is
No Data